Satellos Bioscience (NASDAQ:MSLE) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a report released on Monday morning, Marketbeat reports. The brokerage issued an outperform rating and a $20.00 target price on the stock.

A number of other analysts have also commented on the company. Zacks Research raised Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Cantor Fitzgerald initiated coverage on Satellos Bioscience in a report on Wednesday, March 11th. They set an “overweight” rating for the company. Weiss Ratings initiated coverage on Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating for the company. HC Wainwright boosted their price objective on Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Finally, Wall Street Zen lowered Satellos Bioscience to a “strong sell” rating in a report on Saturday, March 14th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.50.

Satellos Bioscience Price Performance

Shares of MSLE opened at $5.65 on Monday. The company has a market cap of $87.35 million, a price-to-earnings ratio of -3.64 and a beta of 1.37. Satellos Bioscience has a 52 week low of $4.53 and a 52 week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11).

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.